Loading…
Radiopharm Theranostics Limited is projected to rise to $4.82 by 2027, a +10% move from its current price of $4.38. RADX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $4.27 | $4.38 | $4.49 | +0.04% |
| Jul 14 | $4.23 | $4.38 | $4.53 | +0.07% |
| Jul 15 | $4.20 | $4.38 | $4.57 | +0.11% |
| Jul 16 | $4.17 | $4.38 | $4.60 | +0.15% |
| Jul 17 | $4.15 | $4.38 | $4.63 | +0.18% |
| Jul 18 | $4.13 | $4.38 | $4.66 | +0.22% |
| Jul 19 | $4.11 | $4.39 | $4.68 | +0.26% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.11 | $4.39 | $4.68 | +0.26% |
| Week 2 | $4.01 | $4.40 | $4.82 | +0.51% |
| Week 3 | $3.94 | $4.41 | $4.94 | +0.77% |
| Week 4 | $3.88 | $4.42 | $5.04 | +1.02% |
| Week 5 | $3.83 | $4.43 | $5.13 | +1.28% |
| Week 6 | $3.78 | $4.44 | $5.22 | +1.54% |
| Week 7 | $3.74 | $4.45 | $5.30 | +1.80% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Radiopharm Theranostics Limited is a clinical-stage radiotherapeutics company that engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. Its portfolio includes RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic.
The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Radiopharm Theranostics Limited trades under the RADX symbol and has a current price of $4.28. Its market capitalization is $33.74M and it ranks 4742. The forecast shows a year-by-year path with the 2026 average price at $4.28 and rising to a 2050 average of $21.51, with notable upside in later years.
For 2030 the average price is $6.44 and the max is $9.21, with a 50.4% ROI; for 2040 the average is $10.10 with a 135.9% ROI; and for 2050 the average is $21.51 with a 402.6% ROI. The sentiment profile shifts to bullish in 2028 and remains bullish through 2050, indicating a long-horizon uptrend while near-term results remain uncertain.
A major floor 15.5% below — a decisive break under it would weaken the trend.
The nearest floor, 8.1% below — buyers have tended to step in here.
The nearest ceiling, 7.0% above — a clean break opens room to run.
A major ceiling 14.7% above — clearing it would confirm fresh momentum.
Key RADX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RADX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.31 | Buy | $4.32 | Buy |
| MA 10 | $4.25 | Buy | $4.30 | Buy |
| MA 20 | $4.30 | Buy | $4.32 | Buy |
| MA 50 | $4.39 | Sell | $4.40 | Sell |
| MA 100 | $4.54 | Sell | $4.55 | Sell |
| MA 200 | $4.93 | Sell | $4.98 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.31 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 48.77 | Neutral |
| Williams %R (14) | -2.78 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -0.23 | Sell |
| Bollinger %B (20,2) | 0.65 | Neutral |
| Stochastic %K (14) | 97.22 | Sell |
| TRIX (15) | -0.18 | Sell |
| Awesome (5,34) | -0.07 | Sell |
| Ultimate (7,14,28) | 58.49 | Neutral |
| Momentum (10) | 0.04 | Buy |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 4.33 | Buy |
| ADX (14) | 7.36 | Neutral |
| ATR (14) | 0.10 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 50, with the 50-day simple moving average at $4.39 and the 200-day simple moving average at $4.94. Support sits at $4.02 and resistance at $4.68. The 30-day price range spans from a low of $3.63 to a high of $5.05. Annualized volatility stands at 50%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.00 | $4.38 | $5.92 | 0% | Neutral | |
| $3.87 | $4.82 | $6.34 | +10% | Neutral | |
| $4.76 | $6.08 | $8.26 | +39% | Bullish | |
| $5.01 | $6.53 | $9.11 | +49% | Bullish | |
| $5.01 | $6.65 | $9.49 | +52% | Bullish | |
| $5.20 | $7.02 | $10.22 | +61% | Bullish | |
| $4.87 | $6.67 | $9.88 | +53% | Bullish | |
| $5.13 | $7.14 | $10.75 | +63% | Bullish | |
| $5.66 | $7.98 | $12.19 | +82% | Bullish | |
| $6.00 | $8.57 | $13.27 | +96% | Bullish | |
| $6.98 | $10.58 | $17.36 | +142% | Bullish | |
| $13.50 | $22.63 | $40.39 | +417% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $4.00 | $4.38 | $5.35 | +0.00% |
| August 2026 | $3.87 | $4.56 | $5.50 | +4.12% |
| September 2026 | $3.82 | $4.52 | $5.52 | -0.72% |
| October 2026 | $3.92 | $4.67 | $5.75 | +3.30% |
| November 2026 | $4.03 | $4.83 | $5.98 | +3.33% |
| December 2026 | $3.95 | $4.75 | $5.92 | -1.62% |
Click any year to see its month-by-month RADX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, RADX could reach as high as $5.92, with a base case around $4.38 and support toward $4.00 — roughly 0% from $4.38. Price action looks broadly range-bound.
Expect RADX to range from $3.87 to $6.34 through 2027. The $4.82 average target implies a +10% move from current prices. That is up +10% on the projected 2026 average. A consolidation phase looks the most probable path here.
The RADX price prediction for 2028 points to an average of $6.08 (low $4.76, high $8.26) — a potential gain of +39% on today's $4.38. Momentum favours further upside here.
In 2029, RADX is projected to trade between $5.01 and $9.11, averaging $6.53 — a potential gain of +49% from today's $4.38. That is up +7% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Radiopharm Theranostics Limited's 2030 outlook centres on $6.65, within a $5.01 to $9.49 range. That is up +2% on the projected 2029 average. That marks a +52% change versus current levels. Momentum favours further upside here.
By 2031, RADX could reach as high as $10.22, with a base case around $7.02 and support toward $5.20 — roughly +61% from $4.38. Buyers look set to stay in control over this stretch.
Expect RADX to range from $4.87 to $9.88 through 2032. The $6.67 average target implies a +53% move from current prices. That is -5% versus the projected 2031 average. Momentum favours further upside here.
The RADX price prediction for 2033 points to an average of $7.14 (low $5.13, high $10.75) — a potential gain of +63% on today's $4.38. Buyers look set to stay in control over this stretch.
In 2034, RADX is projected to trade between $5.66 and $12.19, averaging $7.98 — a potential gain of +82% from today's $4.38. That is up +12% on the projected 2033 average. Momentum favours further upside here.
Radiopharm Theranostics Limited's 2035 outlook centres on $8.57, within a $6.00 to $13.27 range. That is up +7% on the projected 2034 average. That marks a +96% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, RADX could reach as high as $17.36, with a base case around $10.58 and support toward $6.98 — roughly +142% from $4.38. Momentum favours further upside here.
Expect RADX to range from $13.50 to $40.39 through 2050. The $22.63 average target implies a +417% move from current prices. That is up +114% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in RADX today (≈ 228.571429 RADX) could be worth
$5,173.24
+$4,173.24 (+417%) by 2050 · US Dollar
Based on the average projected RADX price of $22.63 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RADXwould be worth at today's price.
$1,000 invested in RADX on Jul 10, 2025 (≈ 238.095249 RADX) would be worth
$1,041.67
+$41.67 (+4.2%) today · 1.04× · US Dollar
Based on a RADX entry price of $4.2 vs. today's $4.38.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.37 | $1,001.14 | +0.1% |
| 1 month ago | $4.31 | $1,015.08 | +1.5% |
| 3 months ago | $4.66 | $938.84 | -6.1% |
| 6 months ago | $5.15 | $849.51 | -15.0% |
| 1 year ago | $4.2 | $1,041.67 | +4.2% |
| All time (1.6y) ago | $17.67 | $247.59 | -75.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RADX forecast.
Our base-case forecast reaches $8.80 around 2040.
Implied market cap at $8.80: $69.37M
The multi-year forecast paints a bullish trajectory across the horizon. In 2028 the avg price is $5.90 and remains elevated thereafter, with 2029 at $6.33 and 2030 at $6.44 (max $9.21, min $4.84), yielding a 50.4% ROI for 2030. The outlook strengthens toward 2040, where the avg reaches $10.10 (max $16.62) and a 135.9% ROI is projected.
By 2050 the avg is $21.51 (max $38.54) with a 402.6% ROI. These figures accompany a bullish sentiment from 2028 onward. These are estimates, not guarantees, and depend on factors affecting clinical development and market conditions.
Tap a question to reveal the answer.
In 2030 the forecast shows min $4.84, avg $6.44, max $9.21 with a 50.4% ROI and a bullish sentiment.
The forecast indicates bullish sentiment from 2028 onward, with an avg price of $6.44 in 2030 and $21.51 by 2050, and ROI reaching 402.6% by 2050, though these are estimates and not guarantees.
Yes. The 2050 forecast shows an average of $21.51 and a max of $38.54, implying potential to exceed $20 in 2050.
Current price is $4.28 and market cap is $33.74M.
The 30-day picture is NEUTRAL with RSI14 at 50, SMA50 at $4.39, SMA200 at $4.94, support at $4.02, resistance at $4.68, and a 30-day range of $3.63–$5.05; annualized volatility is 50%.
Radiopharm Theranostics Limited Community Discussion
0Share your Radiopharm Theranostics Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.